Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study
Abstract Introduction Psoriasis (PsO), an immune-mediated inflammatory skin disorder, has substantial negative impact on patients’ quality of life. Secukinumab, an approved treatment for moderate-to-severe plaque PsO, has an established long-term efficacy and safety profile. This study aims to provi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2022-12-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-022-00867-y |
| _version_ | 1797453805756874752 |
|---|---|
| author | Hao Trong Nguyen Nhi Thi Uyen Pham Tu Nguyen Anh Tran Nguyen Nhat Pham Yen Thi Bui Thao Thi Phuong Vu |
| author_facet | Hao Trong Nguyen Nhi Thi Uyen Pham Tu Nguyen Anh Tran Nguyen Nhat Pham Yen Thi Bui Thao Thi Phuong Vu |
| author_sort | Hao Trong Nguyen |
| collection | DOAJ |
| description | Abstract Introduction Psoriasis (PsO), an immune-mediated inflammatory skin disorder, has substantial negative impact on patients’ quality of life. Secukinumab, an approved treatment for moderate-to-severe plaque PsO, has an established long-term efficacy and safety profile. This study aims to provide real-world evidence of long-term effectiveness and retention rate of secukinumab in Vietnamese patients with PsO. Methods This retrospective, observational study collected medical records of adult patients with moderate-to-severe PsO receiving secukinumab treatment from Ho Chi Minh City Hospital of Dermato-Venereology. The primary objective was to evaluate secukinumab effectiveness in PsO as measured by 75% improvement in psoriasis area and severity index (PASI 75) at month 12. Secondary objectives were PASI 90/100, absolute PASI ≤ 3 and ≤ 5, Dermatology Life Quality Index (DLQI), and retention rate over 48 months. Results In total, 232 patients with moderate-to-severe PsO met inclusion criteria; 68.1% were male, with median age and age of onset of 39 and 27.5 years, respectively. Median time from onset of PsO to secukinumab treatment was 120 months, 95.3% were prior biologics/disease-modifying antirheumatic drugs naive and 41.4% received concomitant therapies for PsO; 82.3% had national insurance coverage. At month 12, 93.9% of patients achieved PASI 75 (primary endpoint); 80.2/56.9% achieved PASI 90/100; 91.4 and 84.8% patients achieved absolute PASI ≤ 5 and ≤ 3, respectively. The response was sustained over 48 months, with 91.9%/78.0%/52.0% of patients achieving PASI 75/90/100, 89.5% and 82.1% patients achieving absolute PASI ≤ 5 and ≤ 3, respectively. At month 12, 61.4% of patients achieved DLQI 0/1 which was sustained up to month 48 (69.2%). Secukinumab adherence rate of 84.9% at month 12 dropped to 34.2% at month 48. Patients receiving concomitant therapy and national insurance showed higher adherence rate. Conclusion Secukinumab demonstrated long-term effectiveness in real-world Vietnamese patients with moderate-to-severe PsO, with treatment adherence being higher in patients having concomitant therapies and national insurance. |
| first_indexed | 2024-03-09T15:28:11Z |
| format | Article |
| id | doaj.art-544433fbdc1c450d95351823bd3a26cf |
| institution | Directory Open Access Journal |
| issn | 2193-8210 2190-9172 |
| language | English |
| last_indexed | 2024-03-09T15:28:11Z |
| publishDate | 2022-12-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj.art-544433fbdc1c450d95351823bd3a26cf2023-11-26T12:23:54ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722022-12-0113246547610.1007/s13555-022-00867-yLong-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE StudyHao Trong Nguyen0Nhi Thi Uyen Pham1Tu Nguyen Anh Tran2Nguyen Nhat Pham3Yen Thi Bui4Thao Thi Phuong Vu5Ho Chi Minh City Hospital of Dermato-VenereologyHo Chi Minh City Hospital of Dermato-VenereologyHo Chi Minh City Hospital of Dermato-VenereologyHo Chi Minh City Hospital of Dermato-VenereologyNovartis Vietnam Company LimitedHo Chi Minh City Hospital of Dermato-VenereologyAbstract Introduction Psoriasis (PsO), an immune-mediated inflammatory skin disorder, has substantial negative impact on patients’ quality of life. Secukinumab, an approved treatment for moderate-to-severe plaque PsO, has an established long-term efficacy and safety profile. This study aims to provide real-world evidence of long-term effectiveness and retention rate of secukinumab in Vietnamese patients with PsO. Methods This retrospective, observational study collected medical records of adult patients with moderate-to-severe PsO receiving secukinumab treatment from Ho Chi Minh City Hospital of Dermato-Venereology. The primary objective was to evaluate secukinumab effectiveness in PsO as measured by 75% improvement in psoriasis area and severity index (PASI 75) at month 12. Secondary objectives were PASI 90/100, absolute PASI ≤ 3 and ≤ 5, Dermatology Life Quality Index (DLQI), and retention rate over 48 months. Results In total, 232 patients with moderate-to-severe PsO met inclusion criteria; 68.1% were male, with median age and age of onset of 39 and 27.5 years, respectively. Median time from onset of PsO to secukinumab treatment was 120 months, 95.3% were prior biologics/disease-modifying antirheumatic drugs naive and 41.4% received concomitant therapies for PsO; 82.3% had national insurance coverage. At month 12, 93.9% of patients achieved PASI 75 (primary endpoint); 80.2/56.9% achieved PASI 90/100; 91.4 and 84.8% patients achieved absolute PASI ≤ 5 and ≤ 3, respectively. The response was sustained over 48 months, with 91.9%/78.0%/52.0% of patients achieving PASI 75/90/100, 89.5% and 82.1% patients achieving absolute PASI ≤ 5 and ≤ 3, respectively. At month 12, 61.4% of patients achieved DLQI 0/1 which was sustained up to month 48 (69.2%). Secukinumab adherence rate of 84.9% at month 12 dropped to 34.2% at month 48. Patients receiving concomitant therapy and national insurance showed higher adherence rate. Conclusion Secukinumab demonstrated long-term effectiveness in real-world Vietnamese patients with moderate-to-severe PsO, with treatment adherence being higher in patients having concomitant therapies and national insurance.https://doi.org/10.1007/s13555-022-00867-yBiologicsSecukinumabPsoriasisReal-worldEffectiveness |
| spellingShingle | Hao Trong Nguyen Nhi Thi Uyen Pham Tu Nguyen Anh Tran Nguyen Nhat Pham Yen Thi Bui Thao Thi Phuong Vu Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study Dermatology and Therapy Biologics Secukinumab Psoriasis Real-world Effectiveness |
| title | Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study |
| title_full | Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study |
| title_fullStr | Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study |
| title_full_unstemmed | Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study |
| title_short | Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study |
| title_sort | long term effectiveness and drug survival of secukinumab in vietnamese patients with psoriasis results from a retrospective enhance study |
| topic | Biologics Secukinumab Psoriasis Real-world Effectiveness |
| url | https://doi.org/10.1007/s13555-022-00867-y |
| work_keys_str_mv | AT haotrongnguyen longtermeffectivenessanddrugsurvivalofsecukinumabinvietnamesepatientswithpsoriasisresultsfromaretrospectiveenhancestudy AT nhithiuyenpham longtermeffectivenessanddrugsurvivalofsecukinumabinvietnamesepatientswithpsoriasisresultsfromaretrospectiveenhancestudy AT tunguyenanhtran longtermeffectivenessanddrugsurvivalofsecukinumabinvietnamesepatientswithpsoriasisresultsfromaretrospectiveenhancestudy AT nguyennhatpham longtermeffectivenessanddrugsurvivalofsecukinumabinvietnamesepatientswithpsoriasisresultsfromaretrospectiveenhancestudy AT yenthibui longtermeffectivenessanddrugsurvivalofsecukinumabinvietnamesepatientswithpsoriasisresultsfromaretrospectiveenhancestudy AT thaothiphuongvu longtermeffectivenessanddrugsurvivalofsecukinumabinvietnamesepatientswithpsoriasisresultsfromaretrospectiveenhancestudy |